Sanara Medtech Inc (OQ:SMTI)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 1200 Summit Avenue, Suite 414
FORT WORTH TX 76102
Tel: N/A
Website: https://sanaramedtech.com
IR: See website
<
Key People
Ronald T. Nixon
Executive Chairman of the Board
Zachary B. Fleming
Chief Executive Officer
Michael D. McNeil
Chief Financial Officer
Jacob A. Waldrop
Chief Operating Officer
   
Business Overview
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
Financial Overview
For the fiscal year ended 31 December 2023, Sanara Medtech Inc revenues increased 42% to $65M. Net loss decreased 46% to $4.3M. Revenues reflect Soft tissue repair products segment increase of 32% to $54.8M, Bone fusion products segment increase from $4M to $10M. Lower net loss reflects Change in fair value of earnout liabilit decrease from $285K (expense) to $3.4M (income).
Employees: 107 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $288.24M as of Dec 31, 2023
Annual revenue (TTM): $64.99M as of Dec 31, 2023
EBITDA (TTM): -$0.54M as of Dec 31, 2023
Net annual income (TTM): -$4.30M as of Dec 31, 2023
Free cash flow (TTM): -$3.51M as of Dec 31, 2023
Net Debt Last Fiscal Year: $4.55M as of Dec 31, 2023
Shares outstanding: 8,622,805 as of Mar 22, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.